Want to see AU:NSB full AI Analyst Report?
Top Page
Neuroscientific Biopharmaceuticals Ltd.
(Sydney:NSB)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.05
▼(-16.67% Downside)
Action:Reiterated
Date:10/27/26
Overall score is pressured primarily by weak financial performance (recurring losses and worsening cash burn) and bearish technicals (price below all key moving averages with negative MACD). Valuation is also constrained by negative earnings (negative P/E) and lack of dividend support.
Positive Factors
Low Leverage
Minimal debt and no prior-year debt reduce refinancing and interest-rate exposure, while sizable equity relative to assets provides a buffer for operations. This gives NSB more financial flexibility than a highly leveraged biotech, even as losses continue.
Negative Factors
Unstable Revenue Base
Revenue has been inconsistent, including zero revenue in 2022, 2025 and 2026, while the income statement describes no stable commercial base. This weakens visibility into recurring monetization and leaves the company dependent on development progress rather than an established revenue engine.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt and no prior-year debt reduce refinancing and interest-rate exposure, while sizable equity relative to assets provides a buffer for operations. This gives NSB more financial flexibility than a highly leveraged biotech, even as losses continue.
Read all positive factors
Neuroscientific Biopharmaceuticals Ltd. (NSB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$21.04M
Dividend YieldN/A
Average Volume (3M)102.12K
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue GrowthN/A
EPS Growth-10.32%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding389,718,540
10 Day Avg. Volume131,907
30 Day Avg. Volume102,117
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical...
Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.21M | 4.95M | 0.00 |
| Gross Profit | -1.38M | -92.78K | -91.34K | -57.85K | -64.92K |
| EBITDA | -3.72M | -1.92M | -1.80M | -5.96M | -10.37M |
| Net Income | -4.69M | -1.85M | 324.21K | -1.07M | -10.44M |
Balance Sheet | |||||
| Total Assets | 15.18M | 16.96M | 5.44M | 5.29M | 7.74M |
| Cash, Cash Equivalents and Short-Term Investments | 4.63M | 7.27M | 4.95M | 4.91M | 7.22M |
| Total Debt | 87.04K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 374.89K | 149.22K | 85.68K | 597.36K | 2.22M |
| Stockholders Equity | 14.81M | 16.81M | 5.35M | 4.69M | 5.52M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -941.33K | 42.43K | -2.30M | -6.95M |
| Operating Cash Flow | -2.61M | -941.33K | 44.25K | -2.30M | -6.94M |
| Investing Cash Flow | -2.00M | -36.04K | -1.81K | 0.00 | -3.87K |
| Financing Cash Flow | -30.26K | 3.29M | 0.00 | 0.00 | 0.00 |
Neuroscientific Biopharmaceuticals Ltd. Technical Analysis
Negative
0.06
Price Trends
0.06
Negative
0.06
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
7.24
Positive
56.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 7.24 is Positive, neither overbought nor oversold. The STOCH value of 56.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NSB.
Neuroscientific Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.37B | 123.69 | 6.03% | 0.80% | -68.00% | -86.31% | |
52 Neutral | AU$5.95M | -1.58 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$158.84M | -8.54 | -103.42% | ― | ― | 5.88% | |
44 Neutral | AU$55.00M | -2.17 | -48.25% | ― | ― | -16.21% | |
44 Neutral | AU$1.89B | -33.29 | -10.31% | ― | ― | 39.63% | |
42 Neutral | AU$21.04M | -3.88 | -30.02% | ― | ― | -10.32% |
* Healthcare Sector Average
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.05
-0.06
-50.91%
AU:ACW
Actinogen Medical
0.04
<0.01
20.59%
AU:NEU
Neuren Pharmaceuticals Limited
18.70
-2.54
-11.98%
AU:ATH
Alterity Therapeutics
0.24
-0.31
-56.36%
AU:ZLD
Zelira Therapeutics
0.50
0.19
61.29%
AU:PYC
PYC Therapeutics Limited
1.92
0.75
63.96%
Neuroscientific Biopharmaceuticals Ltd. Corporate Events
NeuroScientific Secures FDA Support as StemSmart™ Moves Toward Phase 2
Oct 26, 2026
NeuroScientific Biopharmaceuticals reported that a recent pre‑IND meeting with the U.S. FDA delivered positive feedback on the planned Phase 2 trial of StemSmart™ in refractory Crohn’s disease, confirming the trial design and sup...
NeuroScientific Biopharmaceuticals appoints new CFO as Crohn’s program advances
Oct 21, 2026
NeuroScientific Biopharmaceuticals Ltd., an Australian biotech specialising in immune-mediated inflammatory disorders, is advancing its StemSmart stem cell technology for severe, treatment-resistant Crohn’s disease. The company aims to deliv...
NeuroScientific Wins FDA Backing for StemSmart Crohn’s Trial
Oct 12, 2026
NeuroScientific Biopharmaceuticals has secured positive regulatory feedback from the U.S. Food and Drug Administration on its planned Phase 2 trial of StemSmart in patients with refractory Crohn’s disease in the United States and Australia. ...
NeuroScientific Taps Southern Star to Run Phase 2 Crohn’s Trial
Oct 1, 2026
NeuroScientific Biopharmaceuticals has appointed Australian contract research organisation Southern Star Research to run its planned Phase 2 clinical trial of the StemSmart mesenchymal stem cell platform in patients with refractory Crohn’s d...
NeuroScientific Biopharmaceuticals Sets October 2026 AGM to Review Governance and Board
Sep 8, 2026
NeuroScientific Biopharmaceuticals Ltd has called its Annual General Meeting for 10.00am AWST on 15 October 2026 in Perth, Western Australia. Shareholders eligible to vote will be those on the register as of 5.00pm AWST on 13 October 2026, and the...
NeuroScientific Sets October AGM, Pushes Digital Access and Proxy Voting
Sep 8, 2026
NeuroScientific Biopharmaceuticals Ltd has scheduled its Annual General Meeting for 15 October 2026 at 10:00am AWST in Perth and is encouraging shareholders to participate via directed proxy voting and advance registration. The company will primar...
NeuroScientific Biopharmaceuticals Changes External Auditor Ahead of October AGM
Sep 4, 2026
NeuroScientific Biopharmaceuticals Ltd has announced a change in its external audit arrangements, with Horizon Nexus (WA) Audit Pty Ltd resigning as auditor after receiving consent from the corporate regulator. In.Corp Audit Assurance Pty Ltd has...
Neuroscientific Biopharmaceuticals Lodges Updated ASX Governance Disclosures
Aug 25, 2026
Neuroscientific Biopharmaceuticals Ltd., an ASX-listed biopharmaceutical company developing neuroscience-focused therapies, provides governance information to investors through its website, including its board charter and corporate governance stat...
NeuroScientific Biopharmaceuticals Widens Annual Loss Despite Surge in Income
Aug 25, 2026
NeuroScientific Biopharmaceuticals Limited reported income from ordinary activities of $629,398 for the year ended 30 June 2026, a 278.98% increase on the prior year, but the loss from ordinary activities after tax widened to $4.69 million, reflec...
NeuroScientific Advances StemSmart Crohn’s Program After Promising Patient Results
Jul 28, 2026
NeuroScientific Biopharmaceuticals reported that five patients with fistulising Crohn’s disease treated with its StemSmart therapy under Australia’s Special Access Scheme all improved, with four achieving a clinical response and no ser...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.